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A Weighty Problem*Eric N. Prystowsky, MD, Benzy J. Padanilam, MDT he incidence and prevalence of atrial ﬁbrilla-tion (AF) are increasing globally, and thearrhythmia has profound impact on patient
outcomes (1). The precise reasons for the rising AF
epidemic are unclear, and proposed causes include
the aging population and increased incidence of
risk factors such as hypertension and obesity. Data
showing the link between cardiometabolic risk fac-
tors and AF are accumulating (2–6). The growing
epidemic of obesity could be at the crux of many of
these risk factors, including hypertension, diabetes
mellitus, and obstructive sleep apnea (OSA). Evi-
dence for a causative or contributory role of obesity
in AF could not only change our approach to obese
patients with AF but also change the emphasis on pri-
mary prevention by controlling the obesity epidemic.
The 3 pillars for treatment of AF include anti-
coagulation, rhythm control, and rate control. Clini-
cians are appropriately taught to search for reversible
causes of AF, with the hope that treatment of these
problems may be sufﬁcient to eliminate further AF
episodes. In particular, physicians need to rule out
excessive alcohol intake, hyperthyroidism, and acute
pulmonary issues (7). Therapy needs to be optimized
for conditions associated with AF, such as diabetes
mellitus, hypertension, and lipid disorders. Signs and
symptoms of OSA need to be explored because AF and
OSA commonly occur concomitantly (8). OSA treat-
ment can improve outcomes of catheter ablation
for patients with AF, as well as spontaneous AF*Editorials published in the Journal of the American College of Cardiology
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AF treatment may be right under the clinician’s nose
as they evaluate the patient, although this factor is
often overlooked. This factor is obesity, the treatment
of which has been addressed for patients with AF in
several recent publications.
Abed et al. (5) evaluated the effect of weight loss in
a group of obese patients with paroxysmal or persis-
tent AF. This randomized controlled trial had a me-
dian follow-up of 15 months, and patients entered
into either a physician-led weight loss program
(intervention group) or a self-directed general life-
styles program. The primary outcome was AF symp-
tom burden assessed using the Atrial Fibrillation
Severity Scale (AFSS) instrument, which included
frequency and duration of AF events, as well as a
global episode severity designation. They also used a
7-day Holter monitor. Antiarrhythmic agents were
not randomized, and the approach of rate or rhythm
control was left at the discretion of the physician. The
intervention group had a signiﬁcantly greater reduc-
tion in AF symptom burden, severity, and number of
episodes. Thus, weight loss over a relatively short
follow-up seemed to beneﬁt patients with symp-
tomatic AF. In another study, the same researchers
evaluated the effects of risk factor severity reduction,
including weight reduction, blood pressure control,
lipid management, glycemic control, therapy for OSA,
and alcohol and smoking cessation, on outcomes of
AF ablation (6). Patients had symptomatic AF in spite
of antiarrhythmic therapy and underwent an initial
catheter ablation. Weight reduction and targeted risk
factor management were offered to all patients. The
intervention group consisted of those who under-
went this therapy, and the others constituted the
control group. Importantly, patients in the risk factor
management group had a greater reduction in fre-
quency, duration, and symptoms of AF using the
AFSS scale.
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2171In this issue of the Journal (9), these same in-
vestigators evaluated the longer-term effects of a
goal-directed weight management program in pa-
tients with AF. Of 825 consecutive patients with a
BMI $27 kg/m2 screened, 355 were included. All pa-
tients were given advice on the importance of weight
loss and risk factor management. All patients were
given an opportunity to participate in a physician-led
weight management clinic that included motivational
and goal-directed elements with meal plans and
behavior modiﬁcation. Those not participating par-
ticipated in a self-managed weight loss program. The
initial goal was to reduce weight by 10% with subse-
quent maintenance of the weight loss. Attention also
was given to exercise and management of hyperten-
sion, glucose intolerance, sleep apnea, and smoking
and alcohol use. Three groups were evaluated:
group 1 (n ¼ 135; 10% or greater weight loss); group 2
(n ¼ 103; 3% to 9% weight loss); and group 3
(n ¼ 117; <3% weight loss or weight gain). The effect
of weight ﬂuctuation over time also was studied. Of
note, group 1 patients had a higher participation
(84%) in the dedicated weight management clinic
than the other groups. Although the study was
observational, the different groups served as internal
controls. Patient AF was managed in a dedicated AF
clinic that was independent of the weight manage-
ment clinic. The treating physician made decisions
regarding rate or rhythm management, and the use of
antiarrhythmic agents or catheter ablation did not
differ signiﬁcantly between groups.SEE PAGE 2159The primary outcome was AF symptom burden and
freedom from AF using the AFSS severity scale and a
7-day Holter monitor at yearly follow-up. Secondary
outcomes were assessment of changes in left atrial
volume and left ventricular wall thickness deter-
mined by echocardiography. Although all 3 groups
had improvements in the AF symptom score, the
improvement was signiﬁcantly better in groups 1
and 2 compared with group 3, indicating a dose-
dependent effect. The greater the weight loss, the
better was the outcome. More impressive are the re-
sults of the freedom of AF in the absence of ablation
or antiarrhythmic drug therapy at ﬁnal follow-up.
This was noted in 45.5%, 22.2%, and 13.4% of pa-
tients in groups 1, 2, and 3, respectively (p < 0.001).
However, AF freedom was assessed with only a 7-day
Holter monitor yearly, which likely missed many
asymptomatic episodes, and the true absence from
AF was probably much lower. Nonetheless, all groups
were equally evaluated; therefore, the results are
standardized for this study. Weight loss ﬂuctuationalso mattered, and patients in the weight loss man-
agement clinic had smaller weight ﬂuctuations. Not
only did $5% weight ﬂuctuation adversely affect the
arrhythmia-free survival, it also had a negative
impact on hypertension control, mean fasting insulin
level, high-sensitivity C-reactive protein level, serum
low-density lipoprotein cholesterol level, and cardiac
structural remodeling. Thus, the message is clear:
lose the weight and then keep it off.
Because weight reduction led to fewer AF events,
can we conclude that obesity caused or enabled AF?
Clearly, there is an epidemiological association be-
tween obesity and AF, and the risk of AF rises with
increasing BMI (2,10). There is also evidence for
development of an atrial substrate that supports AF in
patients with obesity (11,12). However, establishing a
causative role for obesity is difﬁcult because the same
interventions that lead to weight loss also improve
the severity of other AF risk markers, such as hyper-
tension, diabetes mellitus, and OSA. Likely the salu-
tary effect of weight reduction on AF occurrence is
multifactorial.
We congratulate the researchers for this important
study that adds further insights into their previous
work on obesity as a potential causative factor for AF.
Long-term weight loss is feasible through physician-
initiated approaches, but the approaches must be
rather rigorous and continued over time. Although it
is not clear which of the many beneﬁts of substantial
weight loss and its maintenance over time contribute
to the reduction of AF burden, there seems little
doubt that it is a positive outcome. Hopefully, future
studies will use more aggressive monitoring (e.g.,
implantable loop recorders) to assess AF burden
reduction more accurately during aggressive lifestyle
changes. A more fundamental question that will
require additional research is whether we can achieve
primary prevention of AF by early attention to factors
such as obesity, diabetes mellitus, hypertension, and
OSA. Also, there are no data on stroke reduction with
these approaches; therefore, it is advisable to main-
tain anticoagulation as per current recommendations
until these data are known.
In summary, clinicians should consider obesity
management as an important strategy to reduce the
AF burden of their patients along with or even before
drug or ablation therapy. In a broader sense,
reversing the obesity epidemic will hopefully turn
back the rising tide of AF.
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